PRDX5 was a risk factor for BCR in prostate cancer patients with greater Gleason score, lymph node metastases, and higher pathological T stage (Figure S5, p < 0.05). This evidence concerns the gene PRDX5 and metastatic malignant neoplasm in the lymph nodes.